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IL-3a b s t r a c t
Immortal mast cell lines, such as RBL-2H3 and HMC-1 cells, are commonly utilized to investigate the
function of mast cells. However, they are tumor cells carrying a gain-of-function mutation of Kit. We
established an immortal mast cell line without Kit mutation, NCL-2, derived from NC mouse bone
marrow. NCL-2 cells could be maintained without additional growth factors and thus could respond
to exogenous growth signals. Moreover, NCL-2 cells expressed FceRI and KIT, and release histamine
and LTB4 in response to antigen stimulation. This cell line could be a useful tool to analyze prolifer-
ation, differentiation, and function of normal mast cells.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mast cells play a pivotal role in type I hypersensitivity reactions
via the high afﬁnity IgE receptors (FceRI) and antigen-speciﬁc IgE.
The crosslinking of FceRI leads to the activation of numerous sig-
naling molecules, SYK, LAT, PLCc, PKC, and ﬁnally results in
degranulation, and arachidonic acid and cytokine production
[1,2]. These mediators are involved in the pathogenesis of allergic
disorders, such as urticaria, atopic dermatitis (AD), allergic rhinitis,
and allergic asthma [2].
Previous studies on the function of mast cells, especially on
degranulation and on signaling pathways mediated by FceRI cross-
linking, have been conducted mostly by the use of RBL-2H3 cells
[3]. RBL-2H3 cells carry a gain-of-function mutation of Kit [4] thus
they do not need exogenous growth factors, such as stem cell fac-
tor (SCF) or interleukin (IL)-3. Investigators can maintain the cells
without expensive recombinant cytokines but they cannot assess
cellular responses against SCF. In addition, it is possible that active
KIT protein could affect other signaling pathways such as FceRI-
mediated signaling events [5]. Moreover, Passante et al. reported
that RBL-2H3 cells share similarities with basophils and thus they
are an imprecise model for mast cell mediator release [6]. MC/9
cells [7], the rodent mast cells without Kit mutation, need IL-3 to
grow. HMC-1 cells, a human mast cell line derived from mast cell
leukemia, carry a gain-of-function mutation of Kit and lack surfaceexpression of FceRI [8]. Another human mast cell line, LAD2 cells,
responds to SCF but grows slowly even in the presence of
100 ng/ml of recombinant human SCF [9].
Here we established NCL-2 mast cell line without a gain-of-
function of Kit mutation, which respond to SCF and IL-3, and re-
lease various chemical mediators against several stimuli including
crosslinking of FceRI.
2. Materials and methods
2.1. Reagents
Recombinant mouse IL-3 (rmIL-3) and stem cell factor (SCF)
were purchased from R&D Systems (Minneapolis, MN, USA). Hu-
man serum albumin (HSA)-conjugated dinitrophenyl (DNP), iono-
mycin, and adenosine triphosphate (ATP) were from Sigma (St.
Louis, MO, USA). Rat DNP-speciﬁc IgE monoclonal antibody was
from Biosource International (Camarillo, CA, USA).
2.2. Animals
Male NC/Kuj mice (6 weeks) were kindly donated by Dr. J.
Hayakawa, Institute for Experimental Animals, School of Medicine,
Kanazawa University, Japan and Balb/c nude mice were purchased
from Charles River Japan (Yokohama, Japan). Mice were main-
tained in closed racks with free access to food and water in the
Institute of Laboratory Animal Science, Hiroshima University. This
study was carried out in accordance with the Guideline for Animal
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for Basic Research and Development (N-BARD), Hiroshima
University.
2.3. Cells
The bone marrow-derived mast cells (BMMC) from 6 weeks old
male mice were generated as previously described [10]. Brieﬂy,
bone marrow cells were suspended at a density of 1  106 cells/
ml in Minimum Essential Medium a (MEMa) (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal calf-serum (FCS), 50 lM 2-
mercaptoethanol, 2 mM L-glutamine, antibiotics (complete
MEMa), and 5 ng/ml IL-3. The cells were cultured for 4 weeks,
replacing half of the existing medium with fresh medium once a
week. After 4 weeks, more than 98% of non-adherent cells were
stained positively by alcian blue. The BMMC were subcultured
about 100 times by 50-fold dilutions in the presence of IL-3. Subse-
quently, the cells were subcultured another 80 times by 100-fold
dilutions without IL-3, and then a single clone (NCL-2) that grew
without IL-3 was obtained by limiting dilution.
P815 murine mastocytoma cells were maintained in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM, Invitrogen) supplemented with
10% FCS and antibiotics.
2.4. Release of histamine and LTB4
NCL-2 cells were incubated in complete MEMa supplemented
with 0.5 lg/ml of DNP-speciﬁc IgE overnight. After washing twice
with complete MEMa, the cells were stimulated with antigen, ion-
omycin or ATP at the indicated concentration for 20 min at 37 C.
The supernatants were transferred into test tubes and centrifuged
at 1500g for 5 min at 4 C to eliminate the cell components.
2.5. Measurement of histamine
After centrifugation, 200 ll of the supernatants were mixed
with equal volumes of 0.5 N perchloric acid to precipitate proteins.
Both cell pellets in test tube and residual cell in culture dishes were
resolved in 1 ml of 0.25 N perchloric acid to recover all residual his-
tamine. Histamine contents in the samples were measured ﬂuoro-
metrically by using an automated histamine analyzing system
(Tosoh Corporation, Osaka, Japan) as described previously [11].
The histamine release was expressed as percentage of total cellular
histamine.
2.6. Measurement of LTB4
The amount of leukotriene B4 (LTB4) in the samples was mea-
sured using enzyme-immunoassay kits (Amersham, Buckingham-
shire, UK). The measurements were performed according to the
manufacture’s instruction. The minimum detectable concentration
of LTB4 was 6.0 pg/ml and cross-reactivity for other related sub-
stances was less than 0.03%. In order to verify the measurement
of LTB4 by enzyme immunoassay, the supernatant of reaction mix-
ture in one experiment was fractionated by reverse phase high per-
formance liquid chromatography (HPLC) as described before [11].
2.7. Western blot analysis
For detection of IL-3-induced tyrosine phosphorylation of Jak2,
2.5  106 NCL-2 cells were stimulated with 100 ng/ml of rmIL-3 for
5 min at 37 C, then quickly centrifuged at 10,000g and lysed in
the sample buffer (62.5 mM Tris–HCl, pH 6.8, 2% sodium dodecyl
sulfate, 10% glycerol, 50 mM DTT, 0.1% bromophenol blue). The
proteins were boiled at 95 C for 5 min, centrifuged at 10,000g
for 10 min, electrophoresed with 5–20% polyacrylamide gel (Atto,Tokyo, Japan), and transferred to a PVDF membrane (Immobilon-
P, Merck Millipore, Billerica, MA, USA). The membrane was incu-
bated with rabbit anti-phospho-JAK2 polyclonal antibody (Bio-
source International, 1:1000 dilution) or anti-JAK2 antibody (Cell
Signaling Technology, Beverly, MA, USA, 1:1000 dilution). After
washed with Tris-buffered saline with Tween 20, the membrane
was incubated with HRP-conjugated anti-rabbit IgG antibody (Cell
Signaling Technology, 1:2000 dilution). The reacted antibodies
were visualized by using ECL (GE Healthcare, Buckinghamshire,
UK) under a luminescent image analyzer (LAS-1000 plus, Fuji Film,
Tokyo, Japan).
For detection of SCF-induced tyrosine phosphorylation of KIT,
NCL-2 cells (2.5  106) were stimulated with 100 ng/ml of rmSCF
for 5 min at 37 C and lysed in 100 ll of the lysis buffer (20 mM
Tris–HCl, pH7.4, 150 mM NaCl, 10% glycerol, 1% NP-40, 1 mM phe-
nylmethylsulphonyl ﬂuoride, 0.15 U/ml aprotinin, 10 mM EDTA,
10 lg/ml leupeptin, 100 mM sodium ﬂuoride, 2 mM sodium ortho-
vanadate) at 4 C for 30 min. Cell lysates were clariﬁed by centri-
fuging for 10 min at 10,000g at 4 C and incubated with 30 ll
of Protein G-Sepharose 4FF (GE Healthcare) to eliminate non-spe-
ciﬁc binding to Protein G. Then the samples were incubated with
rat anti-mouse KIT monoclonal antibody (ACK2, GIBCO-BRL,
1:100 dilution) for 1 h at 4 C. Protein G-Sepharose 4FF was used
to collect the antigen-antibody complexes. These immunoprecipi-
tatants were analyzed by immunoblotting using HRP-conjugated
anti-phosphotyrosine antibody (4G10) (Merck Millipore, 1:2000
dilution) or anti-KIT antibody (ACK2, 1:1000 dilution).
2.8. Flow cytometric analysis of FceRI and KIT
NCL-2 cells (2  105) were suspended in 100 ll of PBS() con-
taining 0.125 lg of FITC-conjugated anti-mouse FceRI antibody,
APC-conjugated anti-mouse KIT antibody (eBioscience, San Diego,
CA, USA), or their isotype controls for 0.5 h on ice. Cells were
washed and analyzed with Attune Acoustic focusing cytometer
(Applied Biosystems, Foster City, CA, USA).
2.9. Tumor growth in mice
NCL-2 and P815 cells (both 1  106) were suspended in 500 ll
of PBS() and were injected subcutaneously into the left hind ﬂank
of Balb/c nude mice. Each tumor size was expressed as a product of
a longest diameter and the shortest diameter. Three mice per
group were used for the experiment.
2.10. DNA sequencing analysis of Kit
A DNA fragment including aspartic acid at codon 814 of Kit was
ampliﬁed by PCR with sense primer: 50-CCGGAATTCGAGACG
TGACTCCTGCCATC-30 and antisense primer: 50-CCGCTCGAGCCCAT
AGGACCAGACATCAC-30. EcoR I site was adapted to the sense pri-
mer and Xho I site was adapted to the antisense primer. EcoR I
and Xho I-digested PCR products were ligated into pME18S cut
with the same enzymes. DNA sequencing of the plasmids was per-
formed with ABI PRISMTM 310 genetic analyzer (Applied Biosys-
tems). There was no substitution of Asp814 in 26 clones.
2.11. RT-PCR analysis of mouse mast cell proteases (mMCPs)
NCL-2 cells (3  103) were incubated with 100 ng/ml of IL-3 or
SCF for 7 days and harvested for the extraction of total RNA with
RNeasy Mini Kit (Qiagen, Hilden, Germany). The reverse transcrip-
tion reaction of RNA was performed with QuantiTect™ reverse
transcription kit (Qiagen). PCR analysis of the expression of mMCPs
in NCL-2 cells were performed with Tks Gﬂex™ DNA polymerase
Fig. 2. NCL-2 cells release mediators in response to various stimuli. NCL-2 cells
were sensitized with anti-DNP IgE, stimulated with DNP-HSA, and then the amount
of histamine (A) and LTB4 (B) released in culture supernatant were measured,
respectively. NCL-2 cells were also stimulated with various concentrations of
ionomycin (C) and ATP (D) and released histamine were measured. Data were
expressed as mean ± SEM of three independent experiments done in duplicate.
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[12].
3. Results
3.1. NCL-2 cells grew without IL-3 or SCF, and expressed FceRI and KIT
on their surface
NCL-2 cells grew independently from exogenous growth factors
except FCS (Fig. 1A). The doubling time of NCL-2 cells calculated by
exponential growth equation was approximately 30.1 h. On the
other hand, P815 cells showed more rapid growth than NCL-2 cells
(Fig. 1B), and the calculated doubling time of P815 cells was
approximately 12 h. The surface expression of FceRI and KIT of
NCL-2 cells were conﬁrmed by ﬂow cytometric analysis (Fig 1C
and D).
3.2. Degranulation and LTB4 production of NCL-2 in response to
various stimuli
Next, we investigated whether NCL-2 could release chemical
mediators in response to various external stimuli including anti-
gens or not. NCL-2 cells were sensitized with anti-DNP IgE and
then simulated with various concentrations of DNP-HSA. As shown
in Fig. 2A and B, NCL-2 cells secreted histamine and produced LTB4
in a dose-dependent manner. NCL-2 cells also showed degranula-
tion in response to ionomycin and ATP as well (Fig. 2C and D).
3.3. Tumorigenic property of NCL-2 cells
We then estimated the tumorigenicity of NCL-2 cells in Balb/c
nude mice. A mouse lymphoblast-like mastocytoma cell line,
P815, showed rapid growth under the skin of nude mice and killedFig. 1. NCL-2 mast cells are immortal and express FceRI and KIT. 1  104/ml of NCL-2 cells (A) and P815 mastocytoma cells (B) were cultured without additional growth
factors except for 10% FCS and the number of cells at each indicated time period was counted. Data were expressed as mean ± SD done in quadricate. NCL-2 cells were stained
with FITC-conjugated anti-mouse FceRI, APC-conjugated anti-mouse KIT, or their isotype controls. Surface expression of FceRI (C) and KIT (D) of NCL-2 cells were shown as
ﬂuorescence intensity histograms (open area: speciﬁc antibodies, ﬁlled area: isotype controls).
Fig. 3. Tumor formation of P815 and NCL-2 mast cell lines in nude mice. P815 and
NCL-2 cells were injected subcutaneously into Balb/c nude mice. The size of each
tumor at indicated time period was expressed as the product of a longest and a
shortest diameter. Data were expressed as mean ± SEM of three mice of each group.
Fig. 5. The expression proﬁles of mMCPs in NCL-2 cells. NCL-2 cells (3  103) were
incubated with 100 ng/ml of IL-3 or SCF for 7 days and harvested for RT-PCR
analysis of the expression of mMCPs. A representative data of three independent
experiments was shown.
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did not form tumors within 16 days. Even after inducing visible tu-
mors, NCL-2 cells grew relatively slowly and did not kill mice at up
to 40 days (Fig. 3).
3.4. Responses to exogenous growth factors, SCF and IL-3
Furthermore, we investigated whether or not NCL-2 cells could
respond to exogenous growth stimuli. NCL-2 cells showed minimal
tyrosine phosphorylation of KIT in quiescent state, and then
showed robust tyrosine phosphorylation of KIT in response to
SCF stimulation (Fig. 4A). NCL-2 cells also showed tyrosine phos-
phorylation of JAK2 in response to IL-3 stimulation (Fig. 4B).
3.5. The change in the expression proﬁle of mMCPs by SCF and IL-3
NCL-2 cells were stimulated with 100 ng/ml of IL-3 and SCF for
7 days and the expression proﬁle of mMCPs were studied. As
shown in Fig. 5, NCL-2 cells, which were maintained without
growth factors, already expressed mMCP-1, 4, 5, and CPA-3. Fur-
thermore, the stimulation with IL-3 and SCF abolished the expres-
sion of mMCP-1, which connective tissue-type mast cells lack to
express [13].Fig. 4. NCL-2 cells respond to exogenous growth factors. (A) NCL-2 cells were
stimulated with 100 ng/ml of SCF for 5 min and lysed. Cell lysates were immuno-
precipitated with anti-KIT antibody. The immunocomplex was electrophoresed and
blotted with anti-phosphotyrosine (anti-pTyr) or anti-KIT antibody. (B) NCL-2 cells
were stimulated with 100 ng/ml of IL-3 for 5 min and lysed. Cell lysates were
electrophoresed and blotted with anti-phosphorylated JAK2 or anti-total JAK2
antibody. A representative data of three independent experiments was shown for
each panel.4. Discussion
In this study, we established an immortal mast cell line, NCL-2,
which can grow in the absence of SCF or IL-3. NCL-2 cells express
KIT and functional FceRI, and release histamine and LTB4 in re-
sponse to antigen stimulation. NCL-2 cells do not have a constitu-
tively active mutation of Kit, thus show slow proliferation in vitro
and substantially indolent tumor growth in vivo as compared with
P815 mastocytoma cells. Moreover, stimulation with SCF and IL-3
induced tyrosine phosphorylation of KIT and JAK2, respectively.
NC mice were established as an inbred strain from Japanese
fancy mice by Kondo in 1955. These mice spontaneously develop
eczema and elevation of serum IgE similar to human AD in the con-
ventional condition and thus are regarded as a mouse model of AD
[14]. We previously reported that BMMC derived from NC/Kuj mice
possess higher histamine content, higher adhesive ability, and
especially, lack of apoptosis upon growth factor deprivation [15].
We, therefore, suspect that a certain population of BMMC from
NCmice may survive without additional growth factors. In the pro-
cess of establishing NCL-2 cells, we also obtained another immortal
cell line, NCL-1, by the same long-term culture of BMMC of NC/Kuj
mice. In contrast to NCL-2 cells, NCL-1 cells possessed an active
mutation of Kit (D814F) on the single allele (data not shown).
The mechanisms of immortality of NCL-2 remained unclear. How-
ever, we should keep in mind that BMMC of NC/Kuj has a potential
to acquire a de novo active mutation of Kit in long-term cultures.
NCL-2 cells contained alcian-blue positive granules but not saf-
ranin-positive granules. Neither IL-3 nor SCF stimulation changed
staining properties of granules even when NCL-2 cells were co-cul-
tured with Swiss 3T3 cells for 2 weeks (data not shown). In general,
BMMC express mMCP-5 and mCPA-3 without SCF, and express
mMCP-4 with SCF [16]. On the other hands, NCL-2 cells express
mMCP-4 without SCF stimulation, implying that NCL-2 cells might
be partially differentiated mast cells. Furthermore, mucosal type
mast cells (MMC) but not connective-tissue type mast cells (CTMC)
express mMCP-1 [13]. IL-3 and SCF stimulation abolished the
expression of mMCP-1, implying that these cytokines might shift
NCL-2 cells towards CTMC-like cells.
In conclusion, NCL-2 cells do not need exogenous growth fac-
tors except for FCS to grow and are a useful tool to analyze both
physiological and pathological functions of mast cells without
the inﬂuence of constitutively active KIT.
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